The recent neoCARHP study demonstrated that in early-stage HER2-positive breast cancer patients receiving dual HER2-blockade, the THP regimen was not inferior to TCbHP in terms of pCR rate while also improving tolerability [20]. The gene discussed is ERBB2; the disease is breast carcinoma.